The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 or Docetaxel; a Retrospective Analysis of a Phase II Trial

Asian Pac J Cancer Prev · 2017 · PMC6373797 · PMID 28669167

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significancep = 0.16not close (p > 0.1)

13.6 months), however the difference did not reach statistical significance (p = 0.16, log rank test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.